TP53 and medulloblastoma: In fact, in this study it was shown that in SHH medulloblastomas there is convergence after radiation therapy on a single altered pathway (TP53 gene and pathway mutations, DYNC1H1 mutations, or chr14q losses) and this finding suggests that it could be possible to develop anticipatory therapy, where individual genes or pathways responsible for therapy resistance are targeted at the time of initial therapy.